Tryptamine Therapeutics (AU:TYP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tryptamine Therapeutics has announced the successful and safe administration of its innovative psilocin-based IV infusion, TRP-8803, to the first obese participant in a Phase 1b study. This trial, conducted in Adelaide, aims to optimize dosing rates and gather valuable data for future Phase 2 trials targeting weight-related conditions. With additional participants to be dosed soon, the company expects interim results later this year.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia Stock Could Take a Beating from Supply Snags on Blackwell Chips
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
